Jennifer Van Eyk

Dr. Jennifer Van Eyk


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JEJoseph E. Ebinger
Joseph E. Ebinger
JFJustyna Fert-Bober
Justyna Fert-Bober
IPIgnat Printsev
Ignat Printsev
MWMin Wu
Min Wu
NSNancy Sun
Nancy Sun
Kimia SobhaniKimia Sobhani
Kimia Sobhani
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

16 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SASubash Adhikari
Subash Adhikari
ENEdouard C. Nice
Edouard C. Nice
EDEric W. Deutsch
Eric W. Deutsch
LLLydie Lane
Lydie Lane
GOGilbert S. Omenn
Gilbert S. Omenn
MBMark S. Baker
Mark S. Baker
The Human Proteome Organization (HUPO) launched the Human Proteome Project (HPP) in 2010, creating an international framework for global collaboration, data sharing, quality assurance and enhancing accurate annotation of the genome-encoded proteome. During the subsequent decade, the HPP established collaborations, developed guidelines and metrics, and undertook reanalysis of previously deposited community data, continuously increasing the coverage of the human proteome. On the occasion of the HPP’s tenth anniversary, we here report a 90.4% complete high-stringency human proteome blueprint. This knowledge is essential for discerning molecular processes in health and disease, as we demonstrate by highlighting potential roles the human proteome plays in our understanding, diagnosis and treatment of cancers, cardiovascular and infectious diseases.

2 March 2023 in Nature Methods
Verified
Journal Article
Closed access
PDF file
LGLaurent Gatto
Laurent Gatto
RARuedi Aebersold
Ruedi Aebersold
JCJuergen Cox
Juergen Cox
VDVadim Demichev
Vadim Demichev
JDJason Derks
Jason Derks
NSNikolai Slavov
Nikolai Slavov

3 February 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
EBEmily G. Baxi
Emily G. Baxi
TTTerri Thompson
Terri Thompson
JLJonathan Li
Jonathan Li
JKJulia A. Kaye
Julia A. Kaye
RLRyan G. Lim
Ryan G. Lim
JRJeffrey D. Rothstein
Jeffrey D. Rothstein
Answer ALS is a biological and clinical resource of patient-derived, induced pluripotent stem (iPS) cell lines, multi-omic data derived from iPS neurons and longitudinal clinical and smartphone data from over 1,000 patients with ALS. This resource provides population-level biological and clinical data that may be employed to identify clinical–molecular–biochemical subtypes of amyotrophic lateral sclerosis (ALS). A unique smartphone-based system was employed to collect deep clinical data, including fine motor activity, speech, breathing and linguistics/cognition. The iPS spinal neurons were blood derived from each patient and these cells underwent multi-omic analytics including whole-genome sequencing, RNA transcriptomics, ATAC-sequencing and proteomics. The intent of these data is for the generation of integrated clinical and biological signatures using bioinformatics, statistics and computational biology to establish patterns that may lead to a better understanding of the underlying mechanisms of disease, including subgroup identification. A web portal for open-source sharing of all data was developed for widespread community-based data analytics.

17 May 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RPRebecca A. Porritt
Rebecca A. Porritt
LPLisa Paschold
Lisa Paschold
MRMagali Noval Rivas
Magali Noval Rivas
MCMary Hongying Cheng
Mary Hongying Cheng
LYLael M Yonker
Lael M Yonker
MAMoshe Arditi
Moshe Arditi
Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory syndrome associated with SARS-CoV-2 infection, shares clinical features with toxic shock syndrome, which is triggered by bacterial superantigens. Superantigen specificity for different Vβ chains results in Vβ skewing, whereby T cells with specific Vβ chains and diverse antigen specificity are overrepresented in the T cell receptor (TCR) repertoire. Here, we characterized the TCR repertoire of MIS-C patients and found a profound expansion of TCRβ variable gene 11-2 (TRBV11-2), with up to 24% of clonal T cell space occupied by TRBV11-2 T cells, which correlated with MIS-C severity and serum cytokine levels. Analysis of TRBJ gene usage and complementarity-determining region 3 (CDR3) length distribution of MIS-C expanded TRBV11-2 clones revealed extensive junctional diversity. Patients with TRBV11-2 expansion shared HLA class I alleles A02, B35, and C04, indicating what we believe is a novel mechanism for CDR3-independent T cell expansion. In silico modeling indicated that polyacidic residues in the Vβ chain encoded by TRBV11-2 (Vβ21.3) strongly interact with the superantigen-like motif of SARS-CoV-2 spike glycoprotein, suggesting that unprocessed SARS-CoV-2 spike may directly mediate TRBV11-2 expansion. Overall, our data indicate that a CDR3-independent interaction between SARS-CoV-2 spike and TCR leads to T cell expansion and possibly activation, which may account for the clinical presentation of MIS-C.

15 October 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RPRebecca A. Porritt
Rebecca A. Porritt
ABAleksandra Binek
Aleksandra Binek
LPLisa Paschold
Lisa Paschold
MRMagali Noval Rivas
Magali Noval Rivas
AMAngela McArdle
Angela McArdle
MAMoshe Arditi
Moshe Arditi
Multisystem inflammatory syndrome in children (MIS-C) manifests as a severe and uncontrolled inflammatory response with multiorgan involvement, occurring weeks after SARS-CoV-2 infection. Here, we utilized proteomics, RNA sequencing, autoantibody arrays, and B cell receptor (BCR) repertoire analysis to characterize MIS-C immunopathogenesis and identify factors contributing to severe manifestations and intensive care unit admission. Inflammation markers, humoral immune responses, neutrophil activation, and complement and coagulation pathways were highly enriched in MIS-C patient serum, with a more hyperinflammatory profile in severe than in mild MIS-C cases. We identified a strong autoimmune signature in MIS-C, with autoantibodies targeted to both ubiquitously expressed and tissue-specific antigens, suggesting autoantigen release and excessive antigenic drive may result from systemic tissue damage. We further identified a cluster of patients with enhanced neutrophil responses as well as high anti-Spike IgG and autoantibody titers. BCR sequencing of these patients identified a strong imprint of antigenic drive with substantial BCR sequence connectivity and usage of autoimmunity-associated immunoglobulin heavy chain variable region (IGHV) genes. This cluster was linked to a TRBV11-2 expanded T cell receptor (TCR) repertoire, consistent with previous studies indicating a superantigen-driven pathogenic process. Overall, we identify a combination of pathogenic pathways that culminate in MIS-C and may inform treatment.